Open for recruitment
Trial summary
Treatment: Drugs - Sapablursen Administered subcutaneously (SC)
Treatment: Drugs - Placebo Administered subcutaneously (SC)
Experimental: Sapablursen - Sapablursen (32 Weeks) - Sapablursen (124 Weeks Open-label)
Experimental: Placebo - Placebo (32 Weeks) - Sapablursen (124 Weeks Open-label)
Trial details
Short title
ONO-0530-03-001
Diagnosis
Myeloproliferative disorders
Type of treatment
Haematology
Phase
III
Locations
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.